K
Kevin P. Maresca
Researcher at Pfizer
Publications - 52
Citations - 2942
Kevin P. Maresca is an academic researcher from Pfizer. The author has contributed to research in topics: Prostate cancer & LNCaP. The author has an hindex of 24, co-authored 48 publications receiving 2646 citations. Previous affiliations of Kevin P. Maresca include Gachon University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Shawn Hillier,Kevin P. Maresca,Frank J. Femia,John C. Marquis,Catherine A. Foss,Nghi Nguyen,Craig Zimmerman,John A. Barrett,William C. Eckelman,Martin G. Pomper,John Joyal,John W. Babich +11 more
TL;DR: Specific binding to PSMA in vivo was shown by competition with PMPA in LNCaP xenografts, and the absence of uptake in PC3 xenografteds.
Journal ArticleDOI
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer.
Kevin P. Maresca,Shawn Hillier,Frank J. Femia,D. Keith,C. Barone,John Joyal,Craig Zimmerman,Alan P. Kozikowski,John A. Barrett,William C. Eckelman,John W. Babich +10 more
TL;DR: Two lead iodine compounds were radiolabeled with (123)I and (131)Iand demonstrated specific PSMA binding on human prostate cancer cells, warranting evaluation as radioligands for the detection, staging, and monitoring of prostate cancer.
Journal ArticleDOI
99mTc-Labeled Small-Molecule Inhibitors of Prostate-Specific Membrane Antigen for Molecular Imaging of Prostate Cancer
Shawn Hillier,Kevin P. Maresca,Genliang Lu,Ross D. Merkin,John C. Marquis,Craig Zimmerman,William C. Eckelman,John Joyal,John W. Babich +8 more
TL;DR: These 99mTc-labeled radiopharmaceuticals targeting PSMA may provide a SPECT molecular imaging option to assist in the initial diagnosis of prostate cancer and the management of patient care by monitoring disease progression.
Journal ArticleDOI
First-in-Man Evaluation of 2 High-Affinity PSMA-Avid Small Molecules for Imaging Prostate Cancer
John A. Barrett,R. Edward Coleman,Stanley J. Goldsmith,Shankar Vallabhajosula,Neil A. Petry,Steve Y. Cho,Thomas Armor,James B. Stubbs,Kevin P. Maresca,Michael G. Stabin,John Joyal,William C. Eckelman,John W. Babich +12 more
TL;DR: These novel radiolabeled small molecules have excellent pharmacokinetic and pharmacodynamic profiles and warrant further development as diagnostic and potentially when labeled with 131I therapeutic radiopharmaceuticals.
Journal ArticleDOI
Bridging the gap between in vitro and in vivo imaging: isostructural Re and 99mTc complexes for correlating fluorescence and radioimaging studies.
Karin A. Stephenson,Sangeeta Ray Banerjee,Travis R. Besanger,Oyebola O. Sogbein,Murali K. Levadala,Nicole McFarlane,Jennifer A. Lemon,Douglas R. Boreham,Kevin P. Maresca,John D. Brennan,John W. Babich,Jon Zubieta,John F. Valliant +12 more
TL;DR: A bifunctional ligand that is capable of forming Re and 99mTc complexes as complementary fluorescent and radioactive probes was developed and was incorporated into fMLFG, a peptide that binds to the formyl peptide receptor (FPR).